Mecasermin is approved for severe primary IGF-1 deficiency in children

What is mecasermin approved for?

Mecasermin, recombinant human IGF-1, is approved for severe primary IGF-1 deficiency in children, a rare condition typically caused by growth hormone receptor defects (Laron syndrome) ^[4]⁠^[5]⁠^[6]⁠^[8].

Children with the condition cannot make their own IGF-1, even with normal or high growth hormone levels ^[4]⁠^[5]⁠^[6]⁠^[8]. The studied population is narrow: children with clinically and often genetically confirmed severe primary IGF-1 deficiency or growth hormone insensitivity ^[4]⁠^[5]⁠^[6]⁠^[8]. It does not include healthy adults seeking muscle gain; for that question, see the growth hormone evidence on body composition and strength.

Why must mecasermin be taken near a meal?

Mecasermin is taken near a meal because it can lower blood glucose, and the product labeling is built around that risk.

IGF-1 is structurally related to insulin and binds the insulin receptor at sufficient concentration. That binding is the physical basis for IGF-1's capacity to drop blood glucose. Hypoglycemia is the headline risk because the mechanism is fast and clean: excess free IGF-1 acting on the insulin receptor.

Why does free IGF-1 matter more than total IGF-1?

Free, unbound IGF-1 drives risk, because only the free fraction can act on the insulin receptor. Most circulating IGF-1 travels bound to IGF-binding proteins ^[1].

IGFBP-3 carries the largest share of bound IGF-1. The binding proteins have signaling roles of their own and are not simply "IGF-1 storage" ^[1].

A cluster-randomized trial in Indonesian adults showed that free IGF-1 moves independently of IGFBP-3. Clearing a chronic helminth infection significantly raised free IGF-1 while leaving IGFBP-3 essentially unchanged ^[2]. Free IGF-1 responds to systemic conditions in ways a simple dose-response model would miss.

Anything that reduces IGF-1's binding to its carrier proteins, physiological or engineered, increases the free fraction available to hit the insulin receptor. That mechanistic thread connects the drug's central warning to the products marketed around it.

What does mecasermin do for children with Laron syndrome?

In children with severe primary IGF-1 deficiency, long-term recombinant IGF-1 increases height velocity and normalizes head circumference growth that had lagged severely behind linear height in untreated patients ^[9].

In one cohort study, head circumference standard deviation scores moved from roughly -3.3 to near 0.9 after treatment, while height deficits closed only partially ^[9].

A review of the treatment's development history notes that catch-up growth under IGF-1 monotherapy tends to be less complete than growth hormone treatment achieves in growth hormone deficiency. The proposed reason is that IGF-1 replacement suppresses the patient's own residual growth hormone output through negative feedback ^[6].

The evidence is real, and it is narrow. It describes a specific rare pediatric population under endocrinologist supervision, and it comes from open-label, long-term series, not large blinded trials.

What dose of mecasermin is used?

Mecasermin is dosed by body weight with slow titration. One long-term treatment protocol in Laron syndrome patients used roughly 150 to 200 micrograms per kilogram once daily ^[9].

That dose belongs to a population whose deficiency has been confirmed by testing, treated under endocrinologist supervision.

What risks does mecasermin carry besides hypoglycemia?

Product labeling and trial reporting for mecasermin describe lymphoid tissue enlargement, intracranial pressure changes, and slipped growth-plate risk in growing bone, beyond hypoglycemia.

The lymphoid tissue enlargement, of the tonsils and adenoids, has been severe enough to prompt surgery in some cases. Forum and vendor pages that borrow "FDA approved" language reliably stop at hypoglycemia and never mention the rest.

The disease itself complicates glucose management. In untreated Laron syndrome, patients show early hypoglycemia tied to their growth hormone receptor defect and progressive obesity, later shifting toward glucose intolerance ^[4]. That natural history is distinct from drug-induced hypoglycemia, and it means clinicians manage glucose risk from two directions at once.

Does mecasermin's safety record apply to IGF-1 LR3?

Mecasermin's safety record does not apply to IGF-1 LR3, a different molecule engineered to resist the binding proteins that normally sequester circulating IGF-1.

Mecasermin is a sequence-verified recombinant protein dosed by body weight in a population whose deficiency has been confirmed by testing ^[4]⁠^[5]⁠^[8]. IGF-1 LR3 and similar research-chemical products are different molecules with no equivalent human trial record.

The mechanism points the wrong way for LR3. Reduced binding-protein engagement raises the free fraction, and the free fraction drives insulin-receptor cross-reactivity. A molecule built to evade binding proteins should therefore be expected to carry the hypoglycemia mechanism more strongly, not less.

IGF-1 LR3 has no comparable human trial record to establish its dosing margins or a titration schedule, and none of the cited studies tested it in humans. The IGF-1 LR3 evidence gap and the IGF-1 DES muscle claims are reviewed separately.

Does IGF-1 cause cancer?

No causal link between IGF-1 and cancer is established, but the signal is unresolved, not absent ^[3]⁠^[7].

Population-level data associate higher circulating IGF-1 and lower IGFBP-3 with several common cancers. GH-IGF1 signaling helps already-transformed cells move through the cell cycle. Large clinical trials targeting this axis directly for cancer treatment have not delivered the benefit preclinical work suggested ^[3]⁠^[7].

Patients homozygous for growth hormone receptor defects, who have had near-absent IGF-1 since birth, show lifelong protection from malignancy in the best-studied cohort, while their heterozygous relatives do not ^[4]. No cited study answers whether restoring IGF-1 through treatment in a previously deficient person changes that protection over decades.

The binding proteins matter outside cancer too. One large cohort study in older men found circulating IGF-1 itself unrelated to incident dementia risk, while higher IGFBP-3 was associated with lower dementia hazard ^[1]. The binding proteins are not inert carriers, and "more IGF-1 is worse" is too simple a summary.